Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edap TMSFOCL -2.25%56 6-1 Month Momentum % is 13.11% as of Aug. 10, 2026. GuruFocus rates FOCL with a GF Score™ of 56/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 125 Medical Distribution companies, Edap TMS ranks better than 84.8% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-10), Edap TMS's 6-1 Month Momentum % is 13.11%.
The industry rank for Edap TMS's 6-1 Month Momentum % or its related term are showing as below:
FOCL's 6-1 Month Momentum % is ranked better than 84.8% of 125
companies
in the Medical Distribution industry
Industry Median: -9.03
vs FOCL: 13.11
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Edap TMS 6-1 Month Momentum % Related Terms
FOCL vs ACH, YI, COSM: 6-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Edap TMS's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS 6-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Edap TMS's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FOCL) has a 6-1 Month Momentum % of 13.11% as of Aug. 10, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #19 out of 125 companies in the Medical Distribution industry, placing it in the top 15.2%.
Is Edap TMS's 6-1 Month Momentum % too high?
Edap TMS's current 6-1 Month Momentum % is 13.11%. Based on the distribution chart, Edap TMS ranks #19 out of 125 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Edap TMS has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's 6-1 Month Momentum % compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #19 out of 125 companies for 6-1 Month Momentum %. This places Edap TMS in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Medical Distribution company?
A good 6-1 Month Momentum % depends on the Medical Distribution industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Edap TMS and its competitors. Edap TMS's current 6-1 Month Momentum % is 13.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.08 — trading 36.6% above its estimated fair value. The current 6-1 Month Momentum % is 13.11%. Edap TMS's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Edap TMS (FOCL), the current 6-1 Month Momentum % is 13.11% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $6.08 is trading 36.6% above its estimated GF Value™ of $4.45.
GuruFocus considers Edap TMS to be Significantly Overvalued.
Key valuation signals for FOCL:
6-1 Month Momentum %: 13.11%
GF Value™: $4.45 vs. price of $6.08 (36.6% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
56GF Score
Get the complete analysis for FOCL
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
